Market capitalization | $526.65m |
Enterprise Value | $398.75m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 4.46 |
P/S ratio (TTM) P/S ratio | 5.89 |
P/B ratio (TTM) P/B ratio | 20.64 |
Revenue growth (TTM) Revenue growth | 15.64% |
Revenue (TTM) Revenue | $89.36m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
7 Analysts have issued a UroGen Pharma Ltd. forecast:
7 Analysts have issued a UroGen Pharma Ltd. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 89 89 |
16%
16%
|
|
Gross Profit | 81 81 |
19%
19%
|
|
EBITDA | -82 -82 |
19%
19%
|
EBIT (Operating Income) EBIT | -84 -84 |
18%
18%
|
Net Profit | -115 -115 |
10%
10%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. Its pipeline includes upper tract urothelial carcinoma, low grade non muscle invasive bladder cancer, carcinoma in situ of the bladder, and overactive bladder. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.
Head office | Israel |
CEO | Elizabeth Barrett |
Employees | 201 |
Founded | 2004 |
Website | www.urogen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.